Adverse drug reactions in liver involve formation of a reactive metabolic intermediary of the drug, binding of the intermediary to macromolecules in the cell, notably proteins in the plasma membrane, immunological response to these altered proteins and attack against hepatocytes bearing these altered proteins by immune mechanisms. At each step in this complex process many factors act to enhance or depress drug metabolism, metabolite disposition, macromolecular binding, neoantigen formation, and the cell mediated and humoral immune attack. The extent and direction of each step may be dose dependent but the complexity of the overall mechanism is so immense that predictability of hepatic drug reactions is unlikely in most instances.
Adverse drug reactions involving the liver were considered originally to be "idiosyncratic" in nature without further defining this term. When allergy became understood as an immunologic phenomenon, the reactions were felt to be the result of hypersensitivity with drugs acting as haptens. As more were seen, the reactions were classified into direct toxicity, cholestasis and viral hepatitis-like [1] . The first was described as the result of dose related injurious action of the drug leading to cell death, the second as the result of impairment of function of the bile secretory apparatus of the hepatocyte, rather than interference with bile flow by ductular obstruction, and the third, as the result of a hypersensitivity reaction. The details of metabolism for many drugs have been elucidated now and intermediary metabolites formed in the hepatocyte have been blamed for injury rather than the drug itself [2] .
The purpose of this paper is to examine aspects of both metabolism and immune responsiveness and to hypothesize how a complex interplay of several factors is probably necessary to produce many of the adverse reactions in the liver. THE METABOLIC FATE OF DRUGS A drug given by mouth is carried to the liver via the portal vein bound to serum proteins, most often albumin. The transfer across the hepatocellular plasma membrane probably requires polysaccharide binding sites on the external surface attached to integral membrane proteins of the hepatocytes. Whether the drug is taken into the cell by endocytosis, by a change in the shape or position of the membrane protein or by dissolution in the lipid bilayer of the membrane is unknown. Once inside the cell the drug is eventually bound to a heme containing cytoplasmic cytochrome in the smooth endoplasmic reticulum. At least two [3] and perhaps many [4] cytochromes are present. The one metabolizing mainly aliphatic compounds is called cytochrome P-450 because its maximal absorbance of light in carbon monoxide atmospheres 489 occurs at 450 nanometers. The one which metabolizes mainly aromatic compounds is called P1 450 or P-448 and is associated with aryl hydrocarbon hydroxylase. These cytochromes in the drug metabolizing enzyme system can be induced by the drug causing a reaction or by other drugs or chemicals [5, 6] . The drug can be oxidized or deacylated by the cytochrome to the form of the drug that is active pharmacologically [7] . Then it is further oxidized and conjugated with glucuronide or if a large amount is present with glutathione. Occasionally the drug moves to the soluble fraction of the cytoplasm where sulfatation or acetylation can occur. Oxidation to Reactive Intermediaries The initial metabolic step involves oxidation at one carbon atom or one double bond with formation of an oxidized intermediary and water. The cytochrome P450 requires molecular oxygen and the enzyme system has been called a "mixed function oxidase." The intermediary which forms in the initial stages of oxidation is an epoxide, a superoxide or a free radical [8, 9] . It usually has a short half life but it can escape further metabolism. The metabolite is very reactive and can bind to cell macromolecules like protein, RNA and DNA. Some of the macromolecules are structural components, some are enzymes and some are informational in nature. The intermediary metabolites of a given drug probably bind preferentially to specific sites on a given macromolecule because toxic reactions are reproducible often even in different species. The effect of such binding depends on the rate of formation of the intermediary as well as on the type of macromolecule bound. The intermediary free radical formed from carbon tetrachloride, for instance, destroys the lipoprotein membrane of the endoplasmic reticulum. The acute centrolobular hepatic necrosis following tumor chemotherapy with such drugs as mithramycin [10] or mitomycin C [11] or from overdosage of acetaminophen [12] probably results from metabolite binding to macromolecules, the last as suggested by Mitchell et al [7, 9] . The rate of formation of metabolites in turn is in part genetically controlled [13, 14] but also individual factors play a role. The amount of enzyme depends directly on the state of protein nutrition [15] and on how much it is induced by environmental pollutants [16] or by preceding drug therapy [6] . Its state of reactivity can be influenced by competition for metabolism by endogenous substances or by other drugs or by hepatocellular injury from disease.
Disposition of Intermediaries
Normally intermediaries are moved by continuation of the oxidative process with the help of enzymes such as epoxide hydrase [17] [20] . Probably many drugs or their metabolites influence the cytoskeletal structure by directly affecting microtubules and microfilaments or by nonspecifically interfering with cellular function. Furthermore interactions of drugs may alter the cell membrane in complex ways so that membrane proteins are internalized or shed. The process of shedding exposes hitherto "unseen" portions of the membrane proteins to the immune system of the body thereby stimulating an immune response. Finally reactive intermediary metabolites of drugs may bind to specific proteins in the plasma membranes like those that are part of the HLA antigen complex. The patient's immune surveillance mechanism may therefore not recognize this altered protein as self and attack the entire cell injuring it or rejecting it. Thus drugs taken up and metabolized by hepatocytes not only alter the internal composition of these cells but also their surfaces. As yet unknown factors govern the rates of synthesis, polymerization and orientation of the cytoskeletal proteins tubulin of microtubules and actin and myosin of microfilaments.
IMMUNOLOGICAL RESPONSE TO PLASMA MEMBRANE ALTERATIONS
The presence of abnormal membrane proteins or the exposure of shed integral membrane proteins or the more easily detached nonessential peripheral membrane proteins may induce humoral antibody formation as well as a cell mediated immune response. Such mechanisms have been proposed for hepatitis B [21, 22] and they may also be suggested to be acting in the drug induced viral hepatitis-like reactions occurring after halothane [23] , methyldopa [24] or isoniazid [25] . Indeed a similar pathogenesis may explain the similar clinical and pathological picture of viral and drug induced hepatitis. In the case of methyldopa, a superoxide anion has been said to be responsible [26] . The nature and intensity of this response depends on the rate of release of the surface proteins, their uptake by macrophages or leukocytes or binding to the surfaces of lymphocytes, their antigenicity and the reactivity of the host immune system. Plasma membrane fragments, such as those that may be released by shedding of cytoplasm from an injured cell, are ingested by Kupffer cells and leukocytes setting up foci of inflammation [27] . Drugs or their metabolites may influence many steps in this complex process by determining the rate at which protein is made available to act as an antigen, the phagocytic ability of macrophages and their lysosomal digestive function, the surface binding of lymphocytes, the rate of antibody formation and the rate of production of specifically cloned lymphocytes and finally the availability of receptor sites on the hepatocellular surface for immune reactions. Drugs even compete with their metabolites in some of these processes.
Hepatocellular injury may play an adjuvant role enhancing immune responsiveness on one hand and a suppressing role on the other by slowing drug metabolism or reducing available receptor sites. The hepatocellular injury also stimulates collagen production and deposition. The fibrosis may play a role in the development of chronic hepatitis first described after long term use of the laxative, oxyphenisatin [28] and now even recognized after prolonged aspirin ingestion [29] . The pericellular fibrosis along with the development of a complete basement membrane may constitute a physical barrier which can interfere with blood-liver exchange of nutrients and oxygen [30] . This barrier may also be protective by keeping antibody molecules and killer lymphocytes away from the hepatocellular surface.
OPPOSING FORCES IN ADVERSE REACTIONS
Opposing forces are active at each step of drug uptake, metabolism and disposition of metabolites as well as at each step of formation of neoantigens and response of the body to these proteins (Table 1) . Genetic factors play a major role in all of these steps but, except for slow and fast acetylaters of some drugs like isoniazid and for congenital defects in immune responsiveness, little is known about genetic control [14, 31] . The rate of the initial step in metabolism can be accelerated by induction of the responsible enzymes by environmental pollutants like pesticides [32] metabolism vary from species to species so that extrapolation of experimental studies to man is possible only if metabolism is similar [35] . PREDICTABILITY OF DRUG REACTIONS Thus to produce cellular injury a drug and its metabolites must wind their way through a devious pathway filled with detours and obstacles as well as rapid slides. Only with the direct toxins are the pathways simple enough to quantitate so that dose relations can be established. With most drugs that cause adverse reactions, predictability itself is not yet possible. Dose relationships probably exist in individual cases and at each step, but these are lost in the complexity of metabolic reactions some of which amplify and others diminish the effect of the drug in question. The multiplicity of effects at each step also makes prevention a distant goal.
